MENARINI-GROUP
10.6.2020 14:56:06 CEST | Business Wire | Press release
Menarini Group, a privately held Italian pharmaceutical and diagnostics company, today announced that is has successfully completed the acquisition of Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics (Nasdaq: STML), for an aggregate cash consideration up to $677 million on a fully diluted basis.
The transaction, which was announced on 4 May 2020, strengthens Menarini’s oncology portfolio with the addition of both commercial and clinical-stage assets. Menarini acquired Stemline for an upfront payment of $11.50 per share in cash and one non-tradeable Contingent Value Right (CVR) that will entitle each holder to an additional $1.00 per share in cash upon completion of the first sale of ELZONRIS in any EU5 country after European Commission approval.
Stemline launched ELZONRIS for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients, two years or older, following the approval by the United States Food and Drug Administration in December 2018. ELZONRIS is a novel targeted therapy directed to the interleukin-3 (IL-3) receptor-α (CD123), a target present on a wide range of malignancies. In parallel, Stemline has been evaluating ELZONRIS in clinical trials in additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), acute myeloid leukemia (AML), and others. Stemline’s additional pipeline candidates include felezonexor (SL-801) (XPO1 inhibitor; Phase 1 in advanced solid tumor patients ongoing) and SL-1001 (RET kinase inhibitor, IND-enabling studies ongoing).
Elcin Barker Ergun, CEO of Menarini Group, commented, “We are very excited to complete the acquisition of Stemline and to welcome their accomplished team to Menarini. The addition of ELZONRIS, which has potential to treat many other malignancies, as well as the other attractive pipeline assets augments our research and development capabilities and will accelerate our efforts to deliver novel oncology therapeutics to patients in need.”
About ELZONRIS®
ELZONRIS® (tagraxofusp), a targeted therapy directed to CD123, is approved by the U.S. Food and Drug Administration (FDA) and commercially available in the U.S. for the treatment of adult and pediatric patients, two years or older, with BPDCN. For full prescribing information in the U.S., visit www.ELZONRIS.com . In Europe, a marketing authorization application (MAA) is under review by the European Medicines Agency (EMA).
ELZONRIS is also being evaluated in additional clinical trials in other CD123+ indications, including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), acute myeloid leukemia (AML), and others are planned including a CD123+ all-comers trial.
About CD123
CD123 is a cell surface target expressed on a wide range of malignancies including blastic plasmacytoid dendritic cell neoplasm (BPDCN), certain myeloproliferative neoplasms (MPNs) including chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF), acute myeloid leukemia (AML) (and potentially enriched in certain AML subsets), myelodysplastic syndrome (MDS), and chronic myeloid leukemia (CML). CD123 has also been reported on multiple myeloma (MM), acute lymphoid leukemia (ALL), hairy cell leukemia (HCL), Hodgkin’s lymphoma (HL), and certain Non-Hodgkin’s lymphomas (NHL). In addition, CD123+ cells have been detected in the tumor microenvironment of several solid tumors as well as in certain autoimmune disorders including cutaneous lupus and scleroderma.
About BPDCN
BPDCN, formerly blastic NK-cell lymphoma, is an aggressive hematologic malignancy, often with cutaneous manifestations, with historically poor outcomes. BPDCN typically presents in the bone marrow and/or skin and may also involve lymph nodes and viscera. The BPDCN cell of origin is the plasmacytoid dendritic cell (pDC) precursor. The diagnosis of BPDCN is based on the immunophenotypic diagnostic triad of CD123, CD4, and CD56, as well as other markers. The World Health Organization (WHO) termed this disease “BPDCN” in 2008; previous names included blastic NK cell lymphoma and agranular CD4+/CD56+ hematodermic neoplasm. For more information, please visit the BPDCN disease awareness website at www.bpdcninfo.com .
About Menarini
The Menarini Group is a leading international pharmaceutical company with a presence in over 100 countries, including a direct presence in over 70 countries. Its global platform extends throughout Europe, Central America, Africa, the Middle East and Asia and generates over $4.2 billion in annual sales. For over 125 years, Menarini has been investing in the development and distribution of pharmaceuticals to serve patients and physicians around the world with a full portfolio of products in the cardiovascular, gastroenterology, metabolic, infectious diseases and anti-inflammatory/analgesic therapeutic areas. Menarini is also committed to oncology, with several new investigational drugs in development for the treatment of a variety of tumors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200610005445/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Empire State Building Observation Deck Debuts New Family Bundle Ticket Options13.7.2026 22:30:00 CEST | Press release
Groups of four can save up to 20% on Observation Deck tickets purchased online The Empire State Building Observation Deck (ESBOD), atop the “World’s Most Famous Building,” announced today new ticket bundle options for families of all ages to save on their visit to the famed New York City landmark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713003884/en/ Empire State Building Observation Deck Debuts New Family Bundle Ticket Options Groups of four who purchase the new Family Ticket Bundle can save up to 20 percent on tickets to the Empire State Building’s iconic 86th and 102nd Floor Observation Decks, with options for express access and flex admission. The Family Ticket Bundle is available online only. “The Empire State Building Observation Deck is one of the best activities for families in NYC with immersive, educational museum exhibits and Manhattan’s best skyline views,” said Dan Rogoski, observatory general manager.
Kinaxis Inc. to Host Second Quarter 2026 Financial Results Conference Call on August 6, 202613.7.2026 22:05:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced that it has scheduled a conference call to discuss its financial results for the second quarter ended June 30, 2026. The call will be hosted on Thursday, August 6, 2026, at 8:30 a.m. Eastern Time by Razat Gaurav, Chief Executive Officer, and Peter Yaraskavitch, Vice President, Financial Planning and Analysis, followed by a question and answer period. The Company will report its financial results for the second quarter after the close of markets on Wednesday, August 5, 2026. CONFERENCE CALL DETAILS DATE: Thursday, August 6, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/854228135 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietar
PagerDuty Announces Arnaud Lagarde, Vice President of EMEA13.7.2026 22:05:00 CEST | Press release
PagerDuty, Inc. (NYSE: PD), a leader in AI-first operations management, today announced the appointment of Arnaud Lagarde as vice president of EMEA. Lagarde will lead PagerDuty’s next phase of growth in the EMEA region, bringing the entire incident management lifecycle to customers across EMEA to solve their biggest digital challenges. “We are thrilled to appoint Arnaud as vice president of EMEA, since he brings a wealth of enterprise sales relationships and years of experience growing this region,” said Todd McNabb, chief revenue officer at PagerDuty. “Arnaud brings a specific combination of deep technical expertise and leadership that will be critical for PagerDuty’s customers, partners and employees. He is a great fit for PagerDuty and we look forward to his impact.” Lagarde brings to the role over 20 years of experience spanning companies like Automation Anywhere, CA Technologies and BMC. Over the past two decades, he has worked closely with founders, investors and executive teams
Samos Energy Acquisition Corporation Announces Closing of $230 Million Initial Public Offering13.7.2026 21:42:00 CEST | Press release
Samos Energy Acquisition Corporation (the “Company”) announced today the closing of its initial public offering (“IPO”) of 23,000,000 units, including the full exercise by the underwriters of their overallotment option to purchase an additional 3,000,000 units. The offering was priced at $10.00 per unit, resulting in gross proceeds to the Company of $230,000,000. The units began trading on the New York Stock Exchange (the “NYSE”) under the ticker symbol “SAMO.U” on July 10, 2026. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one of the Company’s Class A ordinary shares at an exercise price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the NYSE under the symbols “SAMO” and “SAMO.WS,” respectively. Of the proceeds received from the consummation of the initial public offerin
Kina, EU-respondenter optimistiske om fremtidsudsigterne for samarbejde: GT survey13.7.2026 20:46:00 CEST | Pressemeddelelse
Kina og EU har haft etablerede diplomatiske forbindelser i mere end et halvt århundrede. Fra etableringen af formelle diplomatiske forbindelser til udviklingen til et omfattende strategisk partnerskab er Kina-EU-forbindelserne blevet et af de mest indflydelsesrige bilaterale forhold i verden i dag. Ud over Kina gennemførte Global Times Institute (GTI) fra den 16. oktober til den 4. november 2025 en spørgeskemaundersøgelse i 20 EU-medlemsstater, herunder Danmark, Sverige, Spanien, Belgien og Tyskland, ved hjælp af 21 sprog som spansk, fransk, tysk og kinesisk. Mere end 16.300 gyldige spørgeskemaer blev indsamlet. Undersøgelsesdataene viser, at et flertal af befolkningen i både Kina og EU er interesserede i hinandens kulturer, har stor tillid til fremtiden for det kinesisk-europæiske økonomiske og handelsmæssige samarbejde, og støtter styrket samarbejde mellem Kina og EU inden for global styring. Høj grad af bevidsthed og vilje til kommunikation Denne undersøgelse viser, at befolkningen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom